Claims for Patent: 8,333,963

Summary for Patent: 8,333,963

Title:	Method of inhibiting osteoclast activity
Abstract:	Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
Inventor(s):	Anderson; Dirk M (Port Townsend, WA), Galibert; Laurent J (Prevessin Moens, FR)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	12/850,368
Patent Claims:	1. A method of inhibiting RANK-induced osteoclastogenesis in a patient in need thereof, comprising administering to the patient an antagonistic antibody that binds a RANKL polypeptide consisting of SEQ ID NO:8, wherein the patient suffers from a condition selected from the group consisting of bone cancer, multiple myeloma, melanoma and breast cancer, and the antibody is administered in an amount sufficient to inhibit RANK-induced osteoclastogenesis in the patient. 2. The method of claim 1, wherein the patient suffers from multiple myeloma. 3. The method of claim 1, wherein the patient suffers from breast cancer. 4. A method of inhibiting RANK-induced osteoclastogenesis in a patient in need thereof, the method comprising administering to the patient an antagonistic antibody that binds a RANKL polypeptide consisting of SEQ ID NO:8, wherein the patient suffers from a condition selected from the group consisting of squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancer, head and neck cancer and renal cancer, and the antibody is administered in an amount sufficient to inhibit RANK-induced osteoclastogenesis in the patient. 5. The method of claim 4, wherein the patient suffers from prostate cancer. 6. The method of claim 4, wherein the patient suffers from lung cancer. 7. The method of claim 4, wherein the patient suffers from squamous cell carcinoma.

Details for Patent 8,333,963

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2016-12-23
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2016-12-23

International Patent Family for US Patent 8,333,963

Country	Patent Number	Estimated Expiration
Austria	401404
Austria	412746
Austria	497001
Austria	517916
Australia	3988899